Mar. Drugs 2010, 8(7), 2129-2141; doi:10.3390/md8072129

Preclinical Pharmacology of BA-TPQ, a Novel Synthetic Iminoquinone Anticancer Agent

1email, 1email, 1,4email, 1email, 1email, 1email, 1email, 1email, 1email, 2,3email, 1email and 1,3,* email
Received: 8 May 2010; in revised form: 11 June 2010 / Accepted: 8 July 2010 / Published: 13 July 2010
(This article belongs to the Special Issue Marine Drugs as Antitumour Agents)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Marine natural products and their synthetic derivatives represent a major source of novel candidate anti-cancer compounds. We have recently tested the anti-cancer activity of more than forty novel compounds based on an iminoquinone makaluvamine scaffold, and have found that many of the compounds exert potent cytotoxic activity against human cancer cell lines. One of the most potent compounds, BA-TPQ [(11,12),7-(benzylamino)-1,3,4,8-tetrahydropyrrolo[4,3,2-de]quinolin-8(1H)-one], was active against a variety of human cancer cell lines, and inhibited the growth of breast and prostate xenograft tumors in mice. However, there was some toxicity noted in the mice following administration of the compound. In order to further the development of BA-TPQ, and in a search for potential sites of accumulation that might underlie the observed toxicity of the compound, we accomplished preclinical pharmacological studies of the compound. We herein report the in vitro and in vivo pharmacological properties of BA-TPQ, including its stability in plasma, plasma protein binding, metabolism by S9 enzymes, and plasma and tissue distribution. We believe these studies will be useful for further investigations, and may be useful for other investigators examining the use of similar compounds for cancer therapy.
Keywords: marine alkaloid; pharmacokinetics; protein binding; chemotherapy
PDF Full-text Download PDF Full-Text [297 KB, uploaded 13 July 2010 08:58 CEST]

Export to BibTeX |

MDPI and ACS Style

Ezell, S.J.; Li, H.; Xu, H.; Zhang, X.; Gurpinar, E.; Zhang, X.; Rayburn, E.R.; Sommers, C.I.; Yang, X.; Velu, S.E.; Wang, W.; Zhang, R. Preclinical Pharmacology of BA-TPQ, a Novel Synthetic Iminoquinone Anticancer Agent. Mar. Drugs 2010, 8, 2129-2141.

AMA Style

Ezell SJ, Li H, Xu H, Zhang X, Gurpinar E, Zhang X, Rayburn ER, Sommers CI, Yang X, Velu SE, Wang W, Zhang R. Preclinical Pharmacology of BA-TPQ, a Novel Synthetic Iminoquinone Anticancer Agent. Marine Drugs. 2010; 8(7):2129-2141.

Chicago/Turabian Style

Ezell, Scharri J.; Li, Haibo; Xu, Hongxia; Zhang, Xiangrong; Gurpinar, Evrim; Zhang, Xu; Rayburn, Elizabeth R.; Sommers, Charnell I.; Yang, Xinyi; Velu, Sadanandan E.; Wang, Wei; Zhang, Ruiwen. 2010. "Preclinical Pharmacology of BA-TPQ, a Novel Synthetic Iminoquinone Anticancer Agent." Mar. Drugs 8, no. 7: 2129-2141.

Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert